ClinicalTrials.gg
CompletedNCT07042828Updated Jun 29, 2025

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

A Phase 1 interventional study of Bilastine oral dispersible tablets and Bilaxten oral dispersible tablets in Allergic Rhino-Conjunctivitis and Urticaria, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.

02

Conditions studied

  • Allergic Rhino-Conjunctivitis
  • Urticaria

Browse trials for

03

In context

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

This study's enrollment of 42 is below the median of 51 across 104 interventional studies indexed under Urticaria.

Browse Urticaria studies →

Lead sponsor

Humanis Saglık Anonim Sirketi is the lead sponsor of 42 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged between 18 and 45 years (both inclusive).
  • Subjects' weight within normal range according to normal values for (between 18.5 and 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
  • Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III (A)].
  • Subjects having clinically acceptable 12-lead (ECG).
  • Subjects having clinically acceptable chest X-Ray (PA view), if taken.
  • Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  • Subjects having negative urine alcohol test / breath alcohol test.
  • Non-smoker.
  • Subjects willing to adhere to the protocol requirements and to provide written .
  • For male Subjects: Subjects willing to follow approved methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period
  • For Female Subjects:

    • Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
    • for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
  • Subjects having negative urine pregnancy test at screening and negative serum -hCG pregnancy test on admission day of period 01 (only for female subjects).

Exclusion criteria

Exclusion Criteria:

  • to Bilastine or related class of drugs or any of its or heparin.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
  • Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
  • Presence of alcoholism or drug abuse.
  • History or presence of asthma, urticaria or other significant allergic reactions.
  • History or presence of significant gastric and/or duodenal ulceration.
  • History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  • History or presence of cancer or basal or squamous cell carcinoma.
  • Difficulty with donating blood.
  • Difficulty in swallowing solids dosage form like tablets or capsules.
  • Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
  • Major illness within past 3 months.
  • Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
  • Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
  • Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
  • Positive screening test for any one or more: , and .
  • History or presence of significant easy bruising or bleeding.
  • History or presence of significant recent trauma.
  • Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
  • Female subjects who are currently breast feeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Bilastine oral dispersible tablets

    Bilastine 20 mg oral dispersible tablets

    Drug: Bilastine oral dispersible tablets · Drug: Bilaxten oral dispersible tablets

  • Active comparator
    Bilaxten oral dispersible tablets

    Bilaxten 20 mg oral dispersible tablets

    Drug: Bilastine oral dispersible tablets · Drug: Bilaxten oral dispersible tablets

Interventions

  • DrugBilastine oral dispersible tablets

    Bilastine 20 mg oral dispersible tablets

  • DrugBilaxten oral dispersible tablets

    Bilaxten 20 mg oral dispersible tablets

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for Cmax

    Time frame: 24 hours

  2. Area Under the Curve from time zero to time of last measurable concentration (AUC0-t)

    90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for AUC0-t

    Time frame: 24 hours

Secondary outcomes

  1. Area Under the Curve from time zero to time infinite (AUC0-∞)

    Description Statistics

    Time frame: 24 hours

  2. Time to reach peak plasma concentration (Tmax)

    Description Statistics

    Time frame: 24 hours

07

Study locations

1 site
  • Veeda Clinical Research Ltd.
    Ahmedabad, Gujarat 380 051, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jun 29, 2025
StartActual
Apr 30, 2025
Primary completionActual
Jun 16, 2025
CompletionActual
Jun 19, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07042828
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Apr 30, 2025
Primary completion
Jun 16, 2025
Completion
Jun 19, 2025
Last update
Jun 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion